Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14343MR)

This product GTTS-WQ14343MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14343MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ447MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ3964MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ7694MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ9703MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ6153MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ6401MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ11996MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ2384MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW